Table 1.
Eligible Studies Sorted by Publication Date
| Acronyms | Trial | Publication |
|---|---|---|
| UKPDS33 | UK Prospective Diabetes Study 8 | Lancet. 1998;352:837–853. |
| IDNT | Irbesartan in Patients with Nephropathy due to Type 2 Diabetes 9 | N Engl J Med. 2001;345:851–860. |
| RENAAL | Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan 10 | N Engl J Med. 2001;345:861-869. |
| DIABHYCAR | Non–insulin-dependent DIABetes, Hypertension, microalbuminuria or proteinuria, CARdiovascular events, and Ramipril 11 | BMJ. 2004;328:495–500. |
| DAVID | Atherosclerotic Vascular Disease in Diabetics 12 | Eur Heart J. 2004; 25:1845–1852. |
| CARDS | Collaborative Atorvastatin Diabetes Study 13 | Lancet. 2004;364:685–696. |
| BENEDICT | Bergamo Nephrologic Diabetes Complications Trial 14 | N Engl J Med. 2004;351:1941-1951. |
| COSMIC | Comparative Outcomes Study of Metformin Intervention versus Conventional 15 | Diabetes Care. 2005;28:539–543. |
| PROactive | PROspective pioglitAzone Clinical Trial In macroVascular Events 16 | Lancet. 2005;366:1279–1289. |
| FIELD | Fenofibrate Intervention and Event Lowering in Diabetes 17 | Lancet. 2005;366:1849–1861. |
| ASPEN | The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus 18 | Diabetes Care. 2006;29:1478–1485. |
| ADOPT | A Diabetes Outcome Progression Trial 19 | N Engl J Med. 2006;355:2427–2443. |
| ACCORD | Action to Control Cardiovascular Risk in Diabetes 20 | N Engl J Med. 2008;358:2545–2559. |
| ADVANCE | Action in Diabetes and Vascular Disease 21 | N Engl J Med. 2008;358:2560-2572. |
| DIRECT-2 | DIabetic REtinopathy Candesartan Trial 22 | Lancet. 2008;372:1385–1393. |
| JPAD | Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes 23 | JAMA. 2008;300:2134–2141. |
| VADT | Veterans Affairs Diabetes Trial 24 | N Engl J Med. 2009;360:129–139. |
| DIAD | Detection of Ischemia in Asymptomatic Diabetics 25 | JAMA. 2009;301:1547–1555. |
| RECORD | Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes 26 | Lancet. 2009;373:2125–2135. |
| BARI2D | Bypass Angioplasty Revascularization Investigation 2 Diabetes 27 | N Engl J Med. 2009;360:2503–2515. |
| TREAT | Trial to Reduce Cardiovascular Events With Aranesp Therapy 28 | N Engl J Med. 2009;361:2019–2032. |
| ROADMAP | The Randomized Olmesartan and Diabetes Microalbuminuria Prevention 29 | N Engl J Med. 2011;364:907–917. |